Hubei Mailyard Share Co., Ltd Class A

Hubei Mailyard Share Co., Ltd Class A

SSSE:600107
4.37
CNY
-0.38
(-8.00%)
-0.19EPS
2.02BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.69
1.45
1.37
0.92
0.96
1.16
1.25
0.93
1.27
1.18
1.3
0.92
0.66
0.85
Basic EPS, GAAP
0.03
-0.02
0.01
0.01
0.01
0.02
0.11
0.36
0.06
-0.38
-0.17
-0.19
-0.25
-0.18
Free Cash Flow per Basic Share
-0.03
1.47
-0.05
0.22
-0.3
0.07
0.05
0.15
-0.32
-0.3
-0.25
-0.12
-0.09
- -
Dividend per Share
0.05
0.06
0.07
0.04
0.04
0.04
0.04
0.03
0.03
0.04
0.04
0.02
0.02
0.02
Book Value per Share
1.48
1.46
1.46
1.48
1.54
1.57
1.68
2.04
2.08
1.69
1.56
1.37
1.12
1.08
Tangible Book Value per Share
1.25
1.24
1.26
1.26
1.39
1.42
1.59
1.42
1.45
1.34
1.55
1.36
1.11
1.08
Basic Weighted Avg Shares
389
373
344
474
462
360
359
364
381
365
350
358
356
363
Sales/Revenue/Turnover
659
540
471
434
444
418
447
339
486
430
454
330
236
309
Operating Margin (%)
2.68
1.98
9.72
3.22
2.14
2.53
2.43
-2.24
4.44
1.56
-3.96
-11.55
-14.54
-6.11
Depreciation Expense
28
28
24
23
21
19
17
14
24
33
30
19
12
- -
Net Income, GAAP
12
-7
3
5
5
9
39
131
23
-139
-59
-68
-89
-65
Effective Tax Rate (%)
41.06
59.15
58.68
26.87
- -
- -
- -
15
19.25
- -
- -
- -
- -
- -
Profit Margin (%)
1.77
-1.38
0.73
1.09
1.04
2.06
8.82
38.66
4.71
-32.2
-13.1
-20.67
-37.72
-20.95
Working Capital
482
212
209
191
159
173
215
124
165
77
438
346
287
255
LT Debt
132
124
93
62
47
31
23
65
64
52
9
1
9
9
Total Equity
696
563
567
572
593
600
639
768
782
639
592
521
427
413
Return on Invested Capital (%)
0.59
0.66
0.4
0.42
- -
- -
- -
12.87
1.95
- -
- -
- -
- -
- -
Return on Capital (%)
1.27
-1.38
1.24
2.09
- -
- -
- -
15.28
3.47
- -
- -
- -
- -
- -
Return on Common Equity (%)
2.22
-1.41
0.65
0.9
0.85
1.54
6.76
19.58
3.08
-20.43
-10.17
-12.94
-19.93
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
141
141
126
LT Borrowings
9
9
9
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
360
360
360
Market Capitalization
2,228
2,027
2,023

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
557
536
530
Cash, Cash Equivalents & STI
274
252
205
Accounts Receivable, Net
53
71
109
Inventories
170
162
162
Total Current Liabilities
268
284
275
Payables & Accruals
- -
- -
- -
ST Debt
141
141
126
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.13%
-10.77%
-17.94%
Free Cash Flow
-132.56%
-86.15%
-24.06%
Net Income, GAAP
-8.83%
-160.12%
30.82%
Sales/Revenue/Turnover
-4.7%
-3.67%
-28.32%
Total Cash Common Dividend
-10.59%
-9.23%
-21.64%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
130
75
53
72
330
2025
74
55
- -
64
236
2026
81
63
101
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.04
-0.04
-0.06
-0.05
-0.19
2025
-0.02
-0.04
- -
-0.15
-0.25
2026
0.01
-0.05
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.02
2025
- -
- -
- -
- -
0.02
2026
- -
- -
- -
- -
- -

Company Description

CEO
Wen Yan Duan
Full Time Employees
2,151
Sector
Consumer non-durables
Industry
Apparel/Footwear
Address
Meierya Industrial Park Huangshi HB China 435003
IPO Date
Nov 6, 1997
Business
Hubei Mailyard Share Co., Ltd. (600107.SS) engages primarily in the research, development, design, production, and sale of clothing, apparel, textiles, and accessories in China and internationally. The company operates through Apparel and Textiles, Medical, and Other segments, offering fine wool textile products and garments; pharmaceuticals and medical devices; steam production and sales; water and electricity resale; house leasing; hotel investments; and medical and transportation services. Founded in 1993 and headquartered in Huangshi, Hubei Province, China, it targets domestic and export markets with approximately 2,274 employees. Recent developments include ongoing litigation and arbitration related to the sale of its subsidiary Qinghai Zhongyou Health Huijia Pharmaceutical Chain Co., Ltd., with a mediation agreement reached in a related equity transfer dispute adjusting payment terms to 20 million yuan by June 2025; the company also faces regulatory investigations by the CSRC into itself and actual controller Zheng Jiping, alongside implementation of other risk warnings on its shares starting May 2025 and reported net losses in 2024 and third-quarter 2025.